BARCELONA, June 14 (Reuters) - UCB SA's experimental arthritis treatment Cimzia could be priced at a discount to rivals, since the drug has lower production costs, a key scientific investigator on the ...

BRUSSELS, June 26 (Reuters) - Europe's drug watchdog has recommended EU approval of UCB SA's Cimzia drug as a treatment for rheumatoid arthritis, the Belgian company said on Friday, clearing the way ...

The FDA has approved Cimzia (certolizumab pegol; UCB) injection for the treatment of adults with non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation, the first ...

May 15 -- THURSDAY, May 14 (HealthDay News) -- The U.S. Food and Drug Administration has approved Cimzia (certolizumab pegol) to treat moderate-to-severe rheumatoid arthritis, Belgian drug maker UCB ...

Please provide your email address to receive an email when new articles are posted on . Patients with psoriatic arthritis showed long-term efficacy and safety with Cimzia by achieving Disease Activity ...

UCB emerged as a major biopharmaceutical player in the 1990s with the development of blockbuster drugs Zyrtec and Keppra. Throughout the 1990s and early 2000s, UCB transformed from a hybrid ...

(RTTNews) - Biogen Inc. (BIIB) said that it has reached agreement with Xbrane Biopharma to develop, manufacture, and commercialize Xcimzane, a preclinical monoclonal antibody that is a proposed ...

The drugmaker's management consistently understated the problems it faced from FDA. The US pharma Abbott Laboratories, in Abbott Park, Illinois, may be the most immediate beneficiary from UCB's recent ...

Breaking News from the floor of the EULAR Meeting Statins Achieve Similar Secondary Prevention Benefits With and Without RA This finding adds to the growing body of evidence supporting the value of ...